Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options... May 08
This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and once approved, will be available to ... Dec 15
Libtayo is indicated for advanced non-smal cell cancer with PD-L1 Expression of ≥50%... Oct 31
Roche receives FDA approval for the cobas EGFR mutation test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with ... Oct 30
Gavreto is used in treatment of adults with metastatic RET fusion-positive non-small cell lung cancer... Sep 08
Binex will produce olinvacimab at its new 5,000L production line... Sep 03
Two pharma giants come together for developing Global Companion Diagnostics for patients with NSCLC cancer... Jun 25
First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared to chemotherapy, according to data presented today by Dr. M. Reck, Lung Clinic ... Sep 10
-Advertisements-
Friday, June 14, 2024
